Skip to main content
. 2012 Mar;165(6):1891–1903. doi: 10.1111/j.1476-5381.2011.01677.x

Figure 5.

Figure 5

Effects of systemic treatment with A11 on tumour angiogenesis and Tie2 levels. HCT116 human colorectal cancer cells were injected to the flank of nude mice. Animals were treated with A11 using twice daily i.p. injections of 100 µg (high) or 33 µg (low) or by continuous infusion (pumps) of 48 µg per day for 14 days. Bevacizumab (Avastin) given i.p. every other day for 14 days was used as a positive control. Frozen tumours were cryosectioned and stained. (A) Tumour microvessels were visualized by staining with anti-CD31 antibodies. Microvessel density is presented as means ± SEM number of vessels per area. **P < 0.01 significantly different from vehicle control; one-way ANOVA followed by Dunnett's post hoc test. (B) Tie2 protein levels were evaluated using anti-Tie2 antibodies and are presented as mean ± SEM percent of stained area. *P < 0.05 significantly different from vehicle control; one-way ANOVA followed by Dunnett's post hoc test. (C) The ratio between Tie2 levels and microvessel number is presented as means ± SEM. *P < 0.05 significantly different from vehicle control; Student's t-test. (D) Representative images of immunohistochemical staining of angiogenesis (anti-CD31) and Tie2 levels (anti-Tie2).